Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of zoledronic acid and physical activity
on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast
cancer. The primary objective is to compare the percent change in the lumbar spine bone
mineral density (BMD) from baseline to 12 months for women who are randomized to either:
Group A) intravenous zoledronic acid, oral calcium carbonate, and vitamin D, or Group B) a
prescribed physical activity program, oral calcium carbonate and vitamin D.